FindTrial
Sign In

NGM282

BIOLOGICAL8 trials

Sponsors

NGM Biopharmaceuticals, Inc

Conditions

Diabetes MellitusFunctional ConstipationNASH - Nonalcoholic SteatohepatitisNonalcoholic Steatohepatitis (NASH)Primary Biliary CirrhosisPrimary Sclerosing Cholangitis

Phase 1

Phase 1 SAD and MAD Study of NGM282 in Healthy Adult Participants
CompletedNCT01776528
NGM Biopharmaceuticals, IncDiabetes Mellitus
Start: 2013-01-31End: 2013-07-31Updated: 2013-12-31
Study of NGM282 in Subjects With Functional Constipation and Healthy Individuals
CompletedNCT02649062
NGM Biopharmaceuticals, IncFunctional Constipation
Start: 2015-12-31End: 2017-01-31Updated: 2018-03-30

Phase 2

Phase 2 Study of NGM282 in Patients With Type 2 Diabetes
CompletedNCT01943045
NGM Biopharmaceuticals, IncDiabetes Mellitus
Start: 2013-09-30End: 2014-09-30Updated: 2015-11-17
Phase 2 Study of NGM282 in Patients With Primary Biliary Cirrhosis
CompletedNCT02026401
NGM Biopharmaceuticals, IncPrimary Biliary Cirrhosis
Start: 2014-02-28End: 2014-12-31Updated: 2017-03-28
Phase 2b Study of NGM282 Extended Treatment in Patients With Primary Biliary Cirrhosis
CompletedNCT02135536
NGM Biopharmaceuticals, IncPrimary Biliary Cirrhosis
Start: 2014-05-31End: 2016-02-29Updated: 2017-03-28
Study of NGM282 in Patients With Nonalcoholic Steatohepatitis (NASH)
CompletedNCT02443116
NGM Biopharmaceuticals, IncNonalcoholic Steatohepatitis (NASH)
Start: 2015-07-31End: 2020-01-17Updated: 2025-07-23
A Study of NGM282 in Patients With Primary Sclerosing Cholangitis
CompletedNCT02704364
NGM Biopharmaceuticals, IncPrimary Sclerosing Cholangitis
Start: 2016-03-31End: 2017-06-30Updated: 2025-06-17
Evaluation of Efficacy, Safety and Tolerability of Aldafermin in a Phase 2b, Randomized, Double-blind, Placebo-controlled, Multi-center Study In Subjects With Nonalcoholic Steatohepatitis and Stage 2/3 Fibrosis (ALPINE 2/3)
CompletedNCT03912532
NGM Biopharmaceuticals, IncNASH - Nonalcoholic Steatohepatitis
Start: 2019-05-16End: 2021-03-29Updated: 2025-07-03

Related Papers

Breaking Grounds: A Comprehensive Analysis of Cutting-Edge Treatments for Primary Biliary Cirrhosis/Primary Biliary Cholangitis With Futuristic Treatments.
2025-02-24
Utility of AI digital pathology as an aid for pathologists scoring fibrosis in MASH.
2024-11-289 citations
Decreases in cT1 and liver fat content reflect treatment-induced histological improvements in MASH
Journal of Hepatology2024-09-2529 citations
MRI Quantification of Placebo Effect in Nonalcoholic Steatohepatitis Clinical Trials
Radiology2022-11-017 citations
Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2/3): a randomised, double-blind, placebo-controlled, phase 2b trial.
2022-03-2193 citations
Potent suppression of hydrophobic bile acids by aldafermin, an FGF19 analogue, across metabolic and cholestatic liver diseases.
2021-02-1952 citations
The Commensal Microbe V eillonella as a Marker for Response to an FGF19 Analog in NASH
Hepatology2020-08-1489 citations
Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis
Gastroenterology2020-08-08257 citations
NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
2018-03-05323 citations
Targeting bile acids and lipotoxicity for NASH treatment
Hepatology Communications2017-12-0134 citations